亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Thromboresistant-Anticoagulant Extracellular Matrix

技术优势
Stable binding of heparin to ECM through covalent interactionsSimple, cost-efficient and non-toxic reagentsNo alteration of ECM structure
详细技术说明
SHORT DESCRIPTION A novel method for immobilizing heparin on extracellular matrix (ECM) for reducing coagulation in engineered tissues and organs. #materials #biomedical #therapeutics
*Abstract

BACKGROUND 

One of the greatest limitations to organ transplantation occurs when a patients immune system recognizes the transplanted organ as foreign and rejects it. To prevent this from occurring patients are required to take immunosuppressants for the rest of their life. One way to both prevent organ rejection and remove the need for immunosuppressant medication is to use decellularized organ scaffolds. This involves isolating the extracellular matrix (ECM) of a tissue from its cells, leaving an ECM scaffold of the original tissue. By recellularizing the scaffold with a patient's own cells, issues with immune rejection can be eliminated. While using decellularized ECM scaffolds for organ engineering has been a promising strategy for addressing the organ shortage, one major problem has been ensuring that implanted organs receive adequate blood supply without triggering clot formation. 

ABSTRACT 

Northwestern researchers have developed a new method to attach heparin to the ECM scaffolds from decellularized organs, which can help reduce clotting and ensure the survival of implanted organs. Prof. Ameer's group has developed a simple and inexpensive method to immobilize heparin, a potent anticoagulant, to the ECM scaffolds. Their novel method does not utilize any toxic chemicals while generating stable covalent interactions between heparin and ECM. Further, this procedure does not alter ECM structure or elastic properties allowing production of small diameter vascular grafts as well as larger organs. In laboratory tests using the vascular graft model, this innovative ECM-heparin polymer reduced platelet adhesion, inhibited whole blood clotting and supported endothelial cell adhesion. 

*Inventors
Guillermo Ameer*Jason WertheimBin Jiang
*Publications
Jiang B, Akgun B, Lam RC,Ameer GA, Wertheim JA (2015) A Polymer-Extracellular Matrix Composite withImproved Thromboresistance and Recellularization Properties, ActaBiomaterialia, 18: 50-58.
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备